Please provide your email address to receive an email when new articles are posted on . Impulse Dynamics announced it received FDA and CE Mark approval and launched its miniature next-generation ...

A new study suggests the vagus nerve may be one of the heart’s most important defenders against aging. Researchers found that ...

Cytokinetics announced the FDA approval of aficamten to improve functional capacity and symptoms in adults with symptomatic ...

A team of researchers have discovered that a mutation in a ribosomal protein found specifically in heart and skeletal muscle leads to impaired cardiac contractility in mice. The mutation was found to ...

Maintaining the heart’s connection to the vagus nerve may be a key defense against cardiac aging. Researchers showed that ...

The secret to a healthier and "younger" heart lies in the vagus nerve. A recent study coordinated by the Sant'Anna School of ...

"HCM is a heart muscle disease associated with a significant symptom burden. This approval of a new drug, Myqorzo, represents ...

SIOUX CITY (KTIV) - Brad Hedlund has been in and out of appointments with cardiologists dealing with heart failure over the last decade. Hedlund explained his symptoms as “I had no energy. I had no ...

FDA approved CYTK's Myqorzo for oHCM. It reduces heart's pumping ability, has a warning for heart failure and expected to ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has approved MYQORZO™ (aficamten), 5 mg, 10 mg, 15 mg, 20 mg tablets for the treatment of ...